Taken together, our results on the two mouse SLE models, Lyn-deficient and NZB/W F1 mice, prove that the post-disease onset inhibition of IRF5 suppresses the disease course and is especially effective in remission maintenance. Here, IRF5 is linked to systemic lupus erythematosus.